Mannose-binding lectin deficiency increases mortality risk from pneumococcal infection

Jones, R.M.
November 2008
Thorax;Nov2008, Vol. 63 Issue 11, p1011
Academic Journal
The article presents the study showing the increased mortality risk from pneumococcal infection due to deficiency in mannose-binding lectin (MBL). The study highlights the serum level for MBL deficiency and gives suggestion for supplementation therapy which may be an important development in the future.


Related Articles

  • Pneumococcal vaccines WHO position paper - 2012.  // Weekly Epidemiological Record;4/6/2012, Vol. 87 Issue 14, p129 

    The article focuses on a research paper by the World Health Organization (WHO) on pneumococcal vaccines. As stated, incorporating the most recent developments in the field of pneumococcal vaccines the research focuses on the currently available 10-valent and 13-valent conjugate vaccines. It...

  • Preventing Ear Infections.  // Pediatrics for Parents;2004, Vol. 21 Issue 9, p4 

    Cites a study on the role of pneumococcal vaccine in preventing ear infections. Efficacy of the vaccine in managing infections; Evaluation on safety and side-effects following vaccine administration; Comparison on the effect of the vaccine on pneumococcal pneumonia and ear infections.

  • Ear Infection Rates.  // Pediatrics for Parents;Sep/Oct2013, Vol. 29 Issue 9/10, p25 

    The article focuses on the study which shows that the introduction of pneumococcal vaccine has affected the number of ear infections in young children.

  • Absence of association between mannose-binding lectin gene polymorphisms and HIV-1 infection in a Colombian population. Malik, Suneil; Arias, Mauricio; Di Flumeri, Celestino; Garcia, Luis F.; Schurr, Erwin // Immunogenetics;Apr2003, Vol. 55 Issue 1, p49 

    Mannose-binding lectin (MBL) is a calcium-dependent lectin shown to play an important role in innate immunity to infection by activating the classical complement pathway and phagocytosis. In vitro studies have shown that MBL is able to bind to the gp120 HIV-1 surface antigen, and variants of the...

  • Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Claes, Christa; von der Schulenburg, Johann-Matthias Graf; Graf von der Schulenburg, Johann-Matthias // PharmacoEconomics;2003, Vol. 21 Issue 8, p587 

    Background: The introduction of the conjugate vaccine PnC-7 implies that a pneumococcal vaccine is available, for the first time, which also gives children under the age of 2 years reliable protection against invasive pneumococcal infections and offers some protection against...

  • Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) In Older Adults. Sanford, Mark // Drugs;2012, Vol. 72 Issue 9, p1243 

    Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) [PCV13] is approved for protection against pneumococcal disease in children aged 6 weeks to 5 years and adults aged ≥50 years. In randomized trials in adults aged 60-64 years (not previously vaccinated with 23-valent...

  • Bacterial Pneumonia and Pandemic Influenza Planning. Gupta, Ravindra K.; George, Robert; Nguyen-Van-Tam, Jonathan S. // Romanian Journal of Infectious Diseases;2008, Vol. 11 Issue 3, p133 

    Pandemic influenza planning is well under way across the globe. Antiviral drugs and vaccines have dominated the therapeutic agenda. Far less work has been conducted on stockpiling and planning for deployment of antimicrobial drugs against secondary bacterial pneumonia, a cause of substantial...

  • Preventing Myocardial Infarction With Vaccination. Madjid, Mohammad; Musher, Daniel M. // JAMA: Journal of the American Medical Association;5/5/2010, Vol. 303 Issue 17, p1751 

    The authors examine the myths and realities of preventing myocardial infarction with vaccination by examining a study which investigated the effects of vaccination against pneumococcal pneumonia. They offer an overview of the study, as well as its strengths and weaknesses. They emphasize the...

  • Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-Nonsusceptible Streptococcus pneumoniae. Dagan, Ron; Juergens, Christine; Trammel, James; Patterson, Scott; Greenberg, David; Givon-Lavi, Noga; Porat, Nurith; Gurtman, Alejandra; Gruber, William C.; Scott, Daniel A. // Journal of Infectious Diseases;Apr2015, Vol. 211 Issue 7, p1144 

    Background. Pediatric respiratory infections caused by antibiotic-nonsusceptible Streptococcus pneumoniae (ANSP) continue to present an important challenge, even after introduction of 7-valent pneumococcal conjugate vaccine (PCV7). This randomized double-blind trial assessed the potential...


Read the Article


Sign out of this library

Other Topics